Career history of Gregory S. Moss
Former positions of Gregory S. Moss
Companies | Position | Start | End |
---|---|---|---|
KADMON HOLDINGS, INC. | Compliance Officer | 30/08/2019 | 01/06/2022 |
General Counsel | 30/08/2019 | 01/06/2022 | |
Corporate Officer/Principal | 01/01/2015 | 30/08/2019 | |
Corporate Secretary | 30/08/2019 | 01/06/2022 | |
MEIRAGTX HOLDINGS PLC | Director/Board Member | 01/05/2018 | 19/06/2019 |
MeiraGTx Ltd.
MeiraGTx Ltd. Pharmaceuticals: MajorHealth Technology MeiraGTx Ltd. engages in the development of novel gene therapies to transform the lives of patients suffering from acquired and inherited disorders. The company was founded on March 20, 1991 and is headquartered in London, the United Kingdom. | Compliance Officer | 01/04/2015 | 01/12/2016 |
General Counsel | 01/04/2015 | 01/12/2016 |
Training of Gregory S. Moss
Macquarie University | Graduate Degree |
Statistics
International
Cayman Islands | 2 |
United States | 2 |
United Kingdom | 2 |
Operational
Compliance Officer | 2 |
General Counsel | 2 |
Director/Board Member | 1 |
Sectoral
Health Technology | 4 |
Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
MEIRAGTX HOLDINGS PLC | Health Technology |
Private companies | 2 |
---|---|
Kadmon Holdings, Inc.
Kadmon Holdings, Inc. BiotechnologyHealth Technology Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics to address unmet medical need. The company's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. The firms late-stage product candidate KD025, which is an orally administered selective inhibitor of Rho-associated coiled-coil kinase engages in development for the treatment of inflammatory and fibrotic diseases. The firm's a pivotal clinical trial of KD025 is underway in chronic graft-versus-host disease (cGVHD), as well as a Phase 2 clinical trial in systemic sclerosis. It is also developing next-generation immuno-oncology therapies, specifically IL-15 containing fusion proteins, for the treatment of cancer. The company's lead I-O product candidate, KD033, is an anti-PD-L1/IL-15 fusion protein. Kadmon was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY. | Health Technology |
MeiraGTx Ltd.
MeiraGTx Ltd. Pharmaceuticals: MajorHealth Technology MeiraGTx Ltd. engages in the development of novel gene therapies to transform the lives of patients suffering from acquired and inherited disorders. The company was founded on March 20, 1991 and is headquartered in London, the United Kingdom. | Health Technology |
- Stock Market
- Insiders
- Gregory S. Moss
- Experience